Company Cantargia AB

Equities

CANTA

SE0006371126

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Stockholm Other stock markets 08:59:39 26/04/2024 pm IST			5-day change	1st Jan Change
3.45 ^SEK	-0.58%		-7.46%	-7.70%

17/04	Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	CI
10/04	Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	CI

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

Number of employees: 22

Managers	Title	Age	Since
Göran Forsberg CEO	Chief Executive Officer	61	09/14/09
Patrik Renblad DFI	Director of Finance/CFO	54	15/23/15
David Liberg CTO	Chief Tech/Sci/R&D Officer	55	01/15/01
Lars Thorsson CTO	Chief Tech/Sci/R&D Officer	63	01/15/01
Dominique Tersago CTO	Chief Tech/Sci/R&D Officer	62	01/22/01
Liselotte Larsson COO	Chief Operating Officer	61	01/14/01
Nedjad Losic PRN	Corporate Officer/Principal	54	01/21/01

Members of the board	Title	Age	Since
Magnus Nilsson BRD	Director/Board Member	68	26/21/26
Gunnar Magnus Modee Persson CHM	Chairman	64	01/16/01
Damian Marron BRD	Director/Board Member	62	26/21/26
Anders Martin-Löf BRD	Director/Board Member	53	01/18/01
Thoas Michael Fioretos FOU	Founder	66	26/09/26
Karin Leandersson BRD	Director/Board Member	52	01/16/01
Flavia Borellini BRD	Director/Board Member	65	01/20/01
Patricia Delaite BRD	Director/Board Member	61	01/17/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	183,686,684	167,580,300 ( 91.23 %)	0	91.23 %

Name	Equities	%	Valuation
Fjärde AP-fonden 8.027 %	14,743,911	8.027 %	5 M kr
Första AP-fonden 5.738 %	10,540,406	5.738 %	3 M kr
Alecta Pension Insurance Mutual 5.496 %	10,095,992	5.496 %	3 M kr
AVANZA BANK HOLDING AB 4.601 %	8,452,222	4.601 %	3 M kr
Swedbank Robur Fonder AB 3.017 %	5,542,672	3.017 %	2 M kr
Rafi Barsum 1.025 %	1,883,000	1.025 %	614 592 kr
Thoas Michael Fioretos 0.3134 %	575,600	0.3134 %	187 870 kr
Göran Forsberg 0.1657 %	304,412	0.1657 %	99 357 kr
Bengt Jöndell 0.1070 %	196,499	0.1070 %	64 135 kr
Gunnar Magnus Modee Persson 0.1035 %	190,154	0.1035 %	62 064 kr

Cantargia AB

Scheelevägen 27

223 63, Lund

+46 4 62 75 62 60

http://cantargia.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.45 SEK

Average target price

12.67 SEK

Spread / Average Target

+267.15%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CANTARGIA AB	-7.70%	57.8M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs